Home » Stocks » MEIP

MEI Pharma, Inc. (MEIP)

Stock Price: $2.70 USD -0.06 (-2.17%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 304.00M
Revenue (ttm) 40.92M
Net Income (ttm) -63.34M
Shares Out 112.56M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.70
Previous Close $2.76
Change ($) -0.06
Change (%) -2.17%
Day's Open 2.76
Day's Range 2.66 - 2.81
Day's Volume 553,869
52-Week Range 2.29 - 4.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, July 7, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Tina C. Bea...

3 weeks ago - PRNewsWire

SAN DIEGO, July 1, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock ...

1 month ago - PRNewsWire

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other stocks mentioned: CYTR, FBIO, MBIO, MTNB, ORPH
1 month ago - PennyStocks

SAN DIEGO and TOKYO, June 9, 2021 /PRNewswire/ --  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Ki...

1 month ago - PRNewsWire

SAN DIEGO and TOKYO, June 7, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kir...

1 month ago - PRNewsWire

SAN DIEGO, June 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will host an investor and a...

1 month ago - PRNewsWire

SAN DIEGO and TOKYO, May 19, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kir...

2 months ago - PRNewsWire

SAN DIEGO and TOKYO, May 12, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kir...

2 months ago - PRNewsWire

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -33.33% and -46.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended Ma...

2 months ago - PRNewsWire

SAN DIEGO, April 30, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Ro...

3 months ago - PRNewsWire

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:415...

3 months ago - PRNewsWire

SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrati...

3 months ago - PRNewsWire

SAN DIEGO, April 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 20th...

3 months ago - PRNewsWire

SAN DIEGO, March 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Vorucicli...

4 months ago - PRNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: IMAC, SB, TTI, ZIXI
5 months ago - 24/7 Wall Street

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended D...

5 months ago - PRNewsWire

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm ex...

6 months ago - PRNewsWire

MEIP's pracinostat is a disaster; but zandelisib has always been its core asset. If all goes well, zandelisib may be in the market for r/r FL by 2021.

7 months ago - Seeking Alpha

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investiga...

7 months ago - Business Wire

SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended ...

8 months ago - PRNewsWire

SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against th...

9 months ago - Business Wire

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020,...

9 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) and ce...

9 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - October 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 8, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017...

9 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - October 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - October 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - October 6, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - October 5, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017...

9 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - October 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...

9 months ago - Newsfile Corp

TOKYO and SAN DIEGO, Oct. 2, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest bio...

9 months ago - PRNewsWire

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 202...

10 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - September 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ:M...

10 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2...

10 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 18, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

10 months ago - Newsfile Corp

SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc.

10 months ago - PRNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

10 months ago - PRNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

10 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - September 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

10 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (...

10 months ago - Business Wire

MEI Pharma, Inc. (MEIP) CEO Dan Gold on Q4 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAAU, BAR, DBP, DGL, GLD, GLDM, IAU ...
10 months ago - Seeking Alpha

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- MEI Pharma, Inc.

10 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...

10 months ago - Newsfile Corp

SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.

10 months ago - PRNewsWire

NEW YORK, Aug. 27, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

11 months ago - PRNewsWire

About MEIP

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It a... [Read more...]

Industry
Biotechnology
IPO Date
Dec 19, 2003
CEO
Daniel Gold
Employees
51
Stock Exchange
NASDAQ
Ticker Symbol
MEIP
Full Company Profile

Financial Performance

In 2020, MEI Pharma's revenue was $28.91 million, an increase of 488.26% compared to the previous year's $4.92 million. Losses were -$46.02 million, 173.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MEI Pharma stock is "Strong Buy." The 12-month stock price forecast is 9.67, which is an increase of 258.15% from the latest price.

Price Target
$9.67
(258.15% upside)
Analyst Consensus: Strong Buy